Overview

Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research

Status:
Unknown status
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study was intended to assess the efficacy and safety of different Disease-Modifying Antirheumatic Drugs cycle combination regimen using the American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) in managing active adult rheumatoid arthritis.
Phase:
N/A
Details
Lead Sponsor:
Shanxi Medical University
Treatments:
Antirheumatic Agents
Leflunomide
Methotrexate